New psoriasis drug helps fast improvement
Offering hope to thousands of people suffering from the psoriasis skin condition, a trail of a new drug has reported quick and extensive improvement of the disease.
The details published in The Lancet journal showed that 40 percent of people reported a complete clearance of psoriatic plaques after 12 weeks of treatment with the new drug and over 90 percent showed improvement.
People with psoriasis develop thick, red skin with flaky, silver-white patches called scales which can be itchy for sufferers.
"The visible effects of psoriasis can have a major and life-ruining impact on people's confidence and self-esteem," said lead researcher Chris Griffiths, professor of dermatology at University of Manchester in Britain.
The research tested 2,500 people with psoriasis. Half were given a new drug - ixekizumab - either once every two or four weeks. The other half were given a placebo or a widely used drug for psoriasis called etanercept.
"What we saw in this trial was not just the physical aspects of the disease clearing up, but people on the new drug also reporting a marked improvement in their quality of life as they felt more confident and suffered less from itching - far more than in the other two groups," Griffiths added.
Around half of these patients in the trial showed improvement as early as week four of the trial and up to 71 percent had shown a high level of improvement, as measured using a scale called the Psoriasis Area and Severity Index, by week 12.
Ixekizumab is a monoclonal antibody - a cloned antibody - which neutralises the inflammatory effects of an interleukin (IL) a protein in the skin which carries signals to cells - known as (IL)-17A.
This protein is increasingly becoming recognized as one of the causes of the characteristic red, scaly plaques of psoriasis.
The details published in The Lancet journal showed that 40 percent of people reported a complete clearance of psoriatic plaques after 12 weeks of treatment with the new drug and over 90 percent showed improvement.
People with psoriasis develop thick, red skin with flaky, silver-white patches called scales which can be itchy for sufferers.
"The visible effects of psoriasis can have a major and life-ruining impact on people's confidence and self-esteem," said lead researcher Chris Griffiths, professor of dermatology at University of Manchester in Britain.
The research tested 2,500 people with psoriasis. Half were given a new drug - ixekizumab - either once every two or four weeks. The other half were given a placebo or a widely used drug for psoriasis called etanercept.
"What we saw in this trial was not just the physical aspects of the disease clearing up, but people on the new drug also reporting a marked improvement in their quality of life as they felt more confident and suffered less from itching - far more than in the other two groups," Griffiths added.
Around half of these patients in the trial showed improvement as early as week four of the trial and up to 71 percent had shown a high level of improvement, as measured using a scale called the Psoriasis Area and Severity Index, by week 12.
Ixekizumab is a monoclonal antibody - a cloned antibody - which neutralises the inflammatory effects of an interleukin (IL) a protein in the skin which carries signals to cells - known as (IL)-17A.
This protein is increasingly becoming recognized as one of the causes of the characteristic red, scaly plaques of psoriasis.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.